Accro Bioscience is a clinical-stage biotech developing first- and best-in-class small-molecule therapeutics that target regulatory cell death pathways for inflammatory and immune-mediated diseases. Its lead asset, AC-101, is a selective RIPK2 inhibitor being developed for moderate-to-severe ulcerative colitis and has completed Phase I studies in healthy volunteers in Australia and China, plus a Phase Ib/IIa proof-of-concept study in Chinese patients. The company has received IND clearance from the U.S. FDA to proceed with Phase II studies of AC-101. Accro announced a $50 million Series C to fund a Phase IIb trial of AC-101 and to advance other pipeline candidates. The company operates out of New York and Suzhou and describes a multi-asset pipeline originating from a proprietary drug discovery platform focused on regulatory cell death and inflammation. Ongoing clinical progress and the new financing position Accro to advance global development of its lead and follow-on programs.

Total raised

$112M

Funding rounds

3

Latest round

Series C

Latest activity

May 2026